Oesophagogastric cancer

Promising treatment in current cancer trial

Positive preliminary results of a trial of regorafenib for advanced oesophagogastric cancer have been presented at the Gastrointestinal Cancers Symposium in San Francisco.

The trial, INTEGRATE, is being led by the investigator group, Australasian Gastro-Intestinal Trials Group (AGITG), together with colleagues from Korea and Canada and the CTC.

The major outcomes of the trial will be announced in the coming months.

In Australia, there are around 3,400 new cases a year of cancers at the junction between the oesophagus and the stomach. Around 2,400 people a year die from these cancers. New treatment options are urgently needed because when surgery and chemotherapy fail, no other proven effective treatments are available.

The study recruited 152 patients across 54 centres in four countries, to test the potential of regorafenib as a possible treatment.

Said trial chair, Associate Professor Nick Pavlakis (pictured): 'Our ability to co-ordinate the large number of centres is a tribute to the capacity of this Australian trials group.

'Trials like this are critically important in finding better treatments for GI cancers. They're the only way we can establish whether a treatment is effective and safe or not.'

He said clinical trials offer many benefits for participants: 'Patients on trials are looked after very well, and research has also shown they have higher survival rates.

'There's also an altruistic value, where participants are actively helping to improve treatments for future patients.'

View the abstract here

For more information: integrate @ctc.usyd.edu.au

AGITG website


16 January 2015